Several classes of orally administered HDAC inhibitors have been found to attenuate the progression of certain cancers and neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease (Chuang et al., 2009). Here, HDAC9 is linked to Huntington disease.